{"id":"W4410151754","doi":"10.1182/bloodadvances.2025015860","title":"ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Servier; Blood Cancer UK; AOP Orphan; Swedish Orphan Biovitrum; Galecto; Novartis Pharma; Astellas Pharma; Incyte; Celgene; AstraZeneca; Pfizer","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Anemia; Neutropenia; Adverse effect; International Prognostic Scoring System; Phases of clinical research; Clinical trial; Gastroenterology; Surgery; Toxicity; Bone marrow; Myelodysplastic syndromes","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002783963,0.001846752,0.002645367,0.0005888919,0.0005287361,0.001453216,0.0007276679,0.001258599,0.00345528],"category_scores_gemma":[0.001353217,0.0006847545,0.002041091,0.0005034131,0.0009570554,0.001712595,0.0007951304,0.003433341,0.0007519206],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008144874,"about_ca_system_score_gemma":0.001146387,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006041578,"about_ca_topic_score_gemma":0.001024289,"domain_scores_codex":[0.9986756,0.0006923229,0.00007824488,0.000230818,0.0001198543,0.0002030664],"domain_scores_gemma":[0.9987081,0.0002254503,0.0002655828,0.0001296542,0.00008334655,0.0005878017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8651248,0.0818245,0.005677377,0.0003306546,0.001374157,0.0001530674,0.0001522839,0.0007233172,0.009631982,0.000153754,0.0009405143,0.03391371],"study_design_scores_gemma":[0.4464224,0.5345069,0.01396846,0.00002223867,0.0007221149,0.0001631002,0.00005460796,0.000959643,0.00128818,0.0001033942,0.001739911,0.00004914593],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996396,0.0009328267,0.0002077366,0.0002101086,0.0001058237,0.0007379625,0.0004639546,0.00003295685,0.0009125262],"genre_scores_gemma":[0.9938697,0.0007211128,0.0009873523,0.000464345,0.0003787008,0.001156996,0.001040839,0.00001341134,0.001367588],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00345528,"threshold_uncertainty_score":0.01472318,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01639570833985633,"score_gpt":0.29476738531814,"score_spread":0.2783716769782836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}